C12N 2740/13022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/13022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 240 US grants and 208 published applications in this corpus.
Search patents in C12N- Granted patents
- 240
- Published applications
- 208
- Assignees
- 174
- Inventors
- 507
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 4 | 0 |
| 1993 | 1 | 0 |
| 1994 | 6 | 0 |
| 1995 | 4 | 0 |
| 1996 | 10 | 0 |
| 1997 | 14 | 0 |
| 1998 | 21 | 0 |
| 1999 | 13 | 0 |
| 2000 | 13 | 0 |
| 2001 | 15 | 0 |
| 2002 | 12 | 16 |
| 2003 | 10 | 21 |
| 2004 | 12 | 20 |
| 2005 | 3 | 8 |
| 2006 | 4 | 9 |
| 2007 | 4 | 9 |
| 2008 | 10 | 12 |
| 2009 | 6 | 3 |
| 2010 | 7 | 7 |
| 2011 | 2 | 6 |
| 2012 | 6 | 6 |
| 2013 | 3 | 4 |
| 2014 | 3 | 4 |
| 2015 | 3 | 2 |
| 2016 | 3 | 3 |
| 2017 | 1 | 3 |
| 2018 | 3 | 4 |
| 2019 | 4 | 7 |
| 2020 | 4 | 8 |
| 2021 | 2 | 5 |
| 2022 | 5 | 4 |
| 2023 | 1 | 10 |
| 2024 | 5 | 9 |
| 2025 | 7 | 17 |
| 2026 | 2 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Oncolytic virus strain3 Mar 2026US 12,564,633 B2Replimune Limited
- Modified oncolytic virus11 Nov 2025US 12,465,639 B2Replimune Limited GB
- Modified oncolytic virus4 Nov 2025US 12,458,696 B2Replimune Limited
- Delivery of a gene-editing system with a single retroviral particle and methods of generation and use2 Sep 2025US 12,404,505 B2Regeneron Pharmaceuticals, Inc.
- Expression construct10 Sep 2026US 2026/0265777 A1Lentitek Ltd
- Reverse transcriptase mutants and uses thereof6 Aug 2026US 2026/0226433 A1
- Directed evolution of engineered virus-like particles (evlps)23 Jul 2026US 2026/0209747 A1President and Fellows of Harvard College
- Lipid particles with cofusogens and methods of producing and using the same16 Jul 2026US 2026/0199238 A1Sana Biotechnology, Inc.
- Ligands specific for asct116 Jul 2026US 2026/0200988 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Recombination resistant retroviral helper cell and products produced thereby142US 5,124,263 AWisconsin Alumni Research Foundation · 1992
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Genetically engineered vaccine strain89US 5,364,773 AVirogenetics Corporation · 1994
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001